Levodopa–entacapone–carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease
European Journal of Neurology · 2025-01 · 32 (1)
DOI: 10.1111/ene.16582 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 03.12.2024. Verfasst von Mezin Öthman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Levodopa, Parkinson Disease, Carbidopa, Registries. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Levodopa–entacapone–carbidopa intestinal gel (LECIG) was introduced on the Swedish market in 2019. The therapy is aimed at patients with Parkinson's disease (PD) with fluctuations and dyskinesias. Long‐term efficacy and safety data are lacking.
Objective
To investigate the efficacy, tolerability, and safety of LECIG in regular clinical practice for Parkinson's disease in Sweden.
Methods
Real‐world data were collected from the Swedish registry for Parkinson's disease (ParkReg) for all patients reported to receive LECIG during the period from 2019 until 31 August 2022.
Results
A total of 150 patients were identified. Sixty‐one (41%) of 150 patients were females. At the start of treatment, the median age was 73 years (range: 43–86). The median duration since motor symptoms onset was 17 years (IQR: 9). Fifty (33%) of 150 patients switched from another device‐assisted therapy, mostly LCIG (39 patients). Reported complications were mainly related to PEG‐J tube and stoma (30%). Twenty (13.3%) of 150 patients discontinued LECIG and 11 (7.3%) patients died while on LECIG. The Parkinson KinetiGraph scores for bradykinesia, dyskinesia, fluctuations, tremor, and immobility for 53 patients during LECIG showed good therapy control. The median (IQR) p‐Hcy during LECIG was 12 (4.6) μmol/L ( n = 44). The median (IQR) PDQ‐8 summary index during LECIG was 31 (17) ( n = 52). The median (IQR) EQ5D during LECIG was 0.62 (0.32) ( n = 41).
Conclusions
Data from ParkReg covering 150 patients over 3 years show LECIG to be an effective and safe device‐aided therapy for advanced PD. However, the long‐term efficacy and tolerability of LECIG need to be further investigated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden.
- Department of Neurology, Uppsala University Hospital, Uppsala, Sweden.
- Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden.
- Sahlgrenska University Hospital, Gothenburg, Sweden.
- Division of Neurology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Sweden.
- Department of Neurology, Rehabilitation Medicine, Memory and Geriatrics, Skane University Hospital, Lund, Sweden.
ORCID-Profile: Mezin Öthman, Filip Bergquist, Per Odin, Monica Scharfenort, Anders Johansson, Ioanna Markaki, Per Svenningsson, Nil Dizdar, Dag Nyholm
Zitieren
APA
Öthman, M., Bergquist, F., Odin, P., Scharfenort, M., Johansson, A., Markaki, I., Svenningsson, P., Dizdar, N., & Nyholm, D. (2025). Levodopa–entacapone–carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease. European Journal of Neurology, 32(1). https://doi.org/10.1111/ene.16582
Vancouver
Öthman M, Bergquist F, Odin P, Scharfenort M, Johansson A, Markaki I, et al. Levodopa–entacapone–carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease. European Journal of Neurology. 2025;32(1). doi:10.1111/ene.16582
BibTeX
@article{thman2025,
author = {Öthman, Mezin and Bergquist, Filip and Odin, Per and Scharfenort, Monica and Johansson, Anders and Markaki, Ioanna and Svenningsson, Per and Dizdar, Nil and Nyholm, Dag},
title = {Levodopa–entacapone–carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease},
journal = {European Journal of Neurology},
year = {2025},
volume = {32},
number = {1},
doi = {10.1111/ene.16582}
}
EUVIMED